Randall W. Jones, D.Eng. (PhD, MBA) EARLY DETECTION through Screening Population-Based Screening Studies Screening for Prostate Cancer (PCa) continues to
Overview: ProstatIDTM is North America’s first FDA-Cleared Prostate Cancer SCREENING, Detection and Diagnostic AI software. With 94% AUROC (Area under
TeraRecon, on March 18, 2023 CAMBRIDGE, Mass., Mar. 18,2023 /PRNewswire/ — The Eureka Clinical AI platform, from ConcertAI’s TeraRecon, now
FOR IMMEDIATE RELEASE Bot Image, an Omaha-based MRI medical device company has developed an AI-driven medical device CAD software to…
Just released, The Healthcare Disruptor, by Dr. Randall W Jones. Dr. Jones writes about his journey from rural cowboy to medical device expert and CEO challenging the healthcare system with his inventions…
Bot Image Inc: Facilitating Early Detection through Disruptive Technology In undetermined and unsettled times, one must be open to…
DR. RANDALL W. JONES FOUNDER & CEO OF BOT IMAGE, INC From joining the military at a young age to excelling at civilian jobs to…
Bot Image, Inc., a Nebraska and Maine based Artificial Intelligence medical device company, has received FDA-clearance on its ProstatIDTM AI
ProstatID, THE AI software FDA-cleared for not only detection and diagnosis of PCa, but also for screening using bpMRI. Yes,
Bot Image, Inc., a Nebraska and Maine based Artificial Intelligence medical device company (www.botimageai.com), raised the performance bar with its
AI medical device company Bot Image is highlighting the performance of its ProstatID in a study evaluating its ability to detect, diagnose, and screen for prostate cancer.
Dr. Randall Jones, CEO of BotImage and two other AI companies chosen to participate with GE HealthCare presenting during GE’s Innovation
Dr. Randall Jones is one of the speakers this year. Come visit the GE Healthcare Booth #7324 on Nov. 30th at 1:35pm CT.
A prostate cancer diagnosis can be devastating news for the one in seven men who develop the disease in their lifetimes. Annually, 30,000…
We recently sat down with our founder to ask 10 questions about the company, the industry, and what are the options men have when facing…
We recently sat down with our CEO in his library to discuss the mission, vision, and values of Bot Image. We discussed ProstatID and the…
We’re proud to announce that in partnership with our beta testing site, we processed our first test case using the cloud-based architecture on 6/18/2020.
The Bot Image team has been hard at work trying to obtain FDA clearance. We’re excited to announce that we have passed the first major milestone on July 21, 2020.
Trial Site News features the latest coverage of clinical research. Read the article here: